Literature DB >> 23733881

Critical role of dendritic cell-derived IL-27 in antitumor immunity through regulating the recruitment and activation of NK and NKT cells.

Jun Wei1, Siyuan Xia, Huayan Sun, Song Zhang, Jingya Wang, Huiyuan Zhao, Xiaoli Wu, Xi Chen, Jianlei Hao, Xinglong Zhou, Zhengmao Zhu, Xiang Gao, Jian-xin Gao, Puyue Wang, Zhenzhou Wu, Liqing Zhao, Zhinan Yin.   

Abstract

Critical roles of IL-27 in autoimmune diseases and infections have been reported; however, the contribution of endogenous IL-27 to tumor progression remains elusive. In this study, by using IL-27p28 conditional knockout mice, we demonstrate that IL-27 is critical in protective immune response against methyl-cholanthrene-induced fibrosarcoma and transplanted B16 melanoma, and dendritic cells (DCs) are the primary source. DC-derived IL-27 is required for shaping tumor microenvironment by inducing CXCL-10 expression in myeloid-derived suppressor cells and regulating IL-12 production from DCs, which lead to the recruitment and activation of NK and NKT cells resulting in immunological control of tumors. Indeed, reconstitution of IL-27 or CXCL-10 in tumor site significantly inhibits tumor growth and restores the number and activation of NK and NKT cells. In summary, our study identifies a previous unknown critical role of DC-derived IL-27 in NK and NKT cell-dependent antitumor immunity through shaping tumor microenvironment, and sheds light on developing novel therapeutic approaches based on IL-27.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23733881     DOI: 10.4049/jimmunol.1300328

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  IL-27 confers a protumorigenic activity of regulatory T cells via CD39.

Authors:  Young-Jun Park; Heeju Ryu; Garam Choi; Byung-Seok Kim; Eun Sook Hwang; Hun Sik Kim; Yeonseok Chung
Journal:  Proc Natl Acad Sci U S A       Date:  2019-02-04       Impact factor: 11.205

Review 2.  The function of dendritic cells in modulating the host response.

Authors:  L Song; G Dong; L Guo; D T Graves
Journal:  Mol Oral Microbiol       Date:  2017-10-09       Impact factor: 3.563

3.  Epstein-Barr virus-induced gene 3-deficiency leads to impaired antitumor T-cell responses and accelerated tumor growth.

Authors:  Zhenzhen Liu; Jin-Qing Liu; Yun Shi; Xiaotong Zhu; Zhihao Liu; Ming-Song Li; Jianhua Yu; Lai-Chu Wu; Yukai He; Guoqiang Zhang; Xue-Feng Bai
Journal:  Oncoimmunology       Date:  2015-01-09       Impact factor: 8.110

Review 4.  Is AAV-delivered IL-27 a potential immunotherapeutic for cancer?

Authors:  Jin-Qing Liu; Jianmin Zhu; Aiyan Hu; Alaina Zhang; Chunbaixue Yang; Jianyu Yu; Kalpana Ghoshal; Sujit Basu; Xue-Feng Bai
Journal:  Am J Cancer Res       Date:  2020-11-01       Impact factor: 6.166

5.  Interleukin-27 and IFNγ regulate the expression of CXCL9, CXCL10, and CXCL11 in hepatitis.

Authors:  Laëtitia Basset; Sylvie Chevalier; Yannic Danger; Muhammad Imran Arshad; Claire Piquet-Pellorce; Hugues Gascan; Michel Samson
Journal:  J Mol Med (Berl)       Date:  2015-07-23       Impact factor: 4.599

6.  Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy.

Authors:  Jin-Qing Liu; Chengxiang Zhang; Xinfu Zhang; Jingyue Yan; Chunxi Zeng; Fatemeh Talebian; Kimberly Lynch; Weiyu Zhao; Xucheng Hou; Shi Du; Diana D Kang; Binbin Deng; David W McComb; Xue-Feng Bai; Yizhou Dong
Journal:  J Control Release       Date:  2022-03-14       Impact factor: 11.467

Review 7.  Genetic dissection of dendritic cell homeostasis and function: lessons from cell type-specific gene ablation.

Authors:  Peer W F Karmaus; Hongbo Chi
Journal:  Cell Mol Life Sci       Date:  2013-12-24       Impact factor: 9.261

8.  Transcriptional Analysis of the Guinea Pig Mucosal Immune Response to Intravaginal Infection with Herpes Simplex Virus Type 2.

Authors:  Ronald L Veselenak; Gregg N Milligan; Aaron L Miller; Richard B Pyles; Nigel Bourne
Journal:  Virology       Date:  2018-03-28       Impact factor: 3.616

9.  IL-27 improves adoptive CD8+ T cells' antitumor activity via enhancing cell survival and memory T cell differentiation.

Authors:  Miao Ding; Yi Fei; Jianmin Zhu; Ji Ma; Guoqing Zhu; Ni Zhen; Jiabei Zhu; Siwei Mao; Fenyong Sun; Feng Wang; Qiuhui Pan
Journal:  Cancer Sci       Date:  2022-05-18       Impact factor: 6.518

Review 10.  Potential clinical application of interleukin-27 as an antitumor agent.

Authors:  Takayuki Yoshimoto; Yukino Chiba; Jun-Ichi Furusawa; Mingli Xu; Ren Tsunoda; Kaname Higuchi; Izuru Mizoguchi
Journal:  Cancer Sci       Date:  2015-08-06       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.